Burzynski Research Institute Inc., a company primarily engaged in the research and development of Antineoplaston drugs for cancer treatment, has released its Form 10-Q report for the third quarter of 2025. The report provides a detailed overview of the company's financial performance and operational highlights, shedding light on its current challenges and future outlook.
Financial Highlights
Net Loss: The company reported a net loss of approximately $329,000 for the three months ended November 30, 2025, compared to $352,000 for the same period in 2024. For the nine months ended November 30, 2025, the net loss was approximately $994,000, compared to $1,093,000 for the same period in 2024. The reduction in net loss is primarily attributed to a decrease in research and development costs and general and administrative expenses.
Basic and Diluted Loss Per Common Share: The basic and diluted loss per common share was $(0.00) for the three months ended November 30, 2025, consistent with the same period in 2024. For the nine months ended November 30, 2025, the basic and diluted loss per common share was $(0.01), also consistent with the same period in 2024.
Business Highlights
Research and Development Focus: The company continues to focus on the research and development of Antineoplaston drugs for cancer treatment. However, the investigational new drug application (IND) 43742 is currently under a full clinical hold by the FDA, preventing new patient enrollment until the hold is lifted.
Clinical Trials and Regulatory Status: The company's clinical trials, including those for Diffuse Intrinsic Pontine Glioma (DIPG), are on hold due to regulatory issues. The FDA's full clinical hold on IND 43742 significantly impacts the company's ability to conduct trials.
License Agreement Developments: On May 22, 2023, the company entered into a new license agreement granting exclusive rights in the U.S. and Canada for Antineoplaston products. This agreement covers five U.S. patents owned by Dr. Burzynski.
Economic Dependency: The company remains economically dependent on Dr. Burzynski for funding through his medical practice. This dependency is critical as the company has not generated significant revenue and relies on Dr. Burzynski’s contributions for operational needs.
Operational Challenges: The company faces substantial doubt about its ability to continue as a going concern due to recurring operating losses, working capital deficit, and accumulated deficit. The continuation of operations is heavily reliant on Dr. Burzynski’s financial support.
Future Outlook: Management is evaluating strategic options to secure additional capital through equity or debt financing. However, there is no assurance of success in these efforts, and the company may require additional funding until it achieves positive cash flows from operations.
SEC Filing: